Literature DB >> 10222120

Paradoxical locomotor behavior of dopamine D1 receptor transgenic mice.

S Dracheva1, M Xu, K A Kelley, V Haroutunian, G R Holstein, S Haun, J H Silverstein, S C Sealfon.   

Abstract

The behavioral effects of augmenting dopamine D1 receptor expression in the brain were investigated in mice incorporating additional copies of the mouse D1 receptor gene. Two transgenic lines showed increases in brain D1 receptor binding sites, which were greatest in extrastriatal regions. The full D1 agonist SKF 81297, when administered systemically to control animals, stimulated a dose-dependent increase in locomotor activity. In contrast, in D1 receptor overexpressing transgenic mice, this drug caused a marked suppression of locomotion due to a decrease in the frequency of movement initiation. Amphetamine and cocaine induced comparable locomotor activation in both transgenic animals and their control littermates. In the transgenic animals, D1 agonist-induced rearing and climbing behaviors were suppressed. However, on rotarod testing, the agonist-treated transgenic and control mice performed comparably, indicating that sensorimotor coordination was unaffected. These studies demonstrate that altering the levels of D1 receptor expression reverses the effects of D1 agonism on locomotor initiation and rearing. Copyright 1999 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10222120     DOI: 10.1006/exnr.1999.7037

Source DB:  PubMed          Journal:  Exp Neurol        ISSN: 0014-4886            Impact factor:   5.330


  10 in total

Review 1.  Phenotypic studies on dopamine receptor subtype and associated signal transduction mutants: insights and challenges from 10 years at the psychopharmacology-molecular biology interface.

Authors:  John L Waddington; Colm O'Tuathaigh; Gerard O'Sullivan; Katsunori Tomiyama; Noriaki Koshikawa; David T Croke
Journal:  Psychopharmacology (Berl)       Date:  2005-09-29       Impact factor: 4.530

2.  Selective knockout of the casein kinase 2 in d1 medium spiny neurons controls dopaminergic function.

Authors:  Heike Rebholz; Mingming Zhou; Angus C Nairn; Paul Greengard; Marc Flajolet
Journal:  Biol Psychiatry       Date:  2013-01-03       Impact factor: 13.382

3.  Inhibition of 5α-reductase attenuates behavioral effects of D1-, but not D2-like receptor agonists in C57BL/6 mice.

Authors:  Roberto Frau; Giuliano Pillolla; Valentina Bini; Simone Tambaro; Paola Devoto; Marco Bortolato
Journal:  Psychoneuroendocrinology       Date:  2012-08-09       Impact factor: 4.905

4.  A mutation in CLOCK leads to altered dopamine receptor function.

Authors:  Sade Spencer; Melissa I Torres-Altoro; Edgardo Falcon; Rachel Arey; Marian Marvin; Matthew Goldberg; James A Bibb; Colleen A McClung
Journal:  J Neurochem       Date:  2012-07-27       Impact factor: 5.372

5.  Characterization of PF-6142, a Novel, Non-Catecholamine Dopamine Receptor D1 Agonist, in Murine and Nonhuman Primate Models of Dopaminergic Activation.

Authors:  Rouba Kozak; Tamás Kiss; Keith Dlugolenski; David E Johnson; Roxanne R Gorczyca; Kyle Kuszpit; Brian D Harvey; Polina Stolyar; Stacey J Sukoff Rizzo; William E Hoffmann; Dmitri Volfson; Mihaly Hajós; Jennifer E Davoren; Amanda L Abbott; Graham V Williams; Stacy A Castner; David L Gray
Journal:  Front Pharmacol       Date:  2020-07-07       Impact factor: 5.810

6.  c-Fos is an intracellular regulator of cocaine-induced long-term changes.

Authors:  Ming Xu
Journal:  Ann N Y Acad Sci       Date:  2008-10       Impact factor: 5.691

Review 7.  Modeling the positive symptoms of schizophrenia in genetically modified mice: pharmacology and methodology aspects.

Authors:  Maarten van den Buuse
Journal:  Schizophr Bull       Date:  2009-11-09       Impact factor: 9.306

Review 8.  Behavioral genetic contributions to the study of addiction-related amphetamine effects.

Authors:  Tamara J Phillips; Helen M Kamens; Jeanna M Wheeler
Journal:  Neurosci Biobehav Rev       Date:  2007-11-29       Impact factor: 8.989

Review 9.  Do Dopaminergic Impairments Underlie Physical Inactivity in People with Obesity?

Authors:  Alexxai V Kravitz; Timothy J O'Neal; Danielle M Friend
Journal:  Front Hum Neurosci       Date:  2016-10-14       Impact factor: 3.169

10.  Cell specific photoswitchable agonist for reversible control of endogenous dopamine receptors.

Authors:  Prashant Donthamsetti; Nils Winter; Adam Hoagland; Cherise Stanley; Meike Visel; Stephan Lammel; Dirk Trauner; Ehud Isacoff
Journal:  Nat Commun       Date:  2021-08-06       Impact factor: 14.919

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.